Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349651 | 0.91 | S1PR1 (0.49) | S1PR1HSD17B10KDM4EPOLBTSHR | |
| SCHEMBL211174 | 0.80 | SMN1; SMN2 (0.36) | L3MBTL1HSD17B10KDM4EPOLBALDH1A1 | |
| SCHEMBL212267 | 0.78 | HPGD (0.36) | MAPTKDM4EPOLBALDH1A1MAPK1 | |
| SCHEMBL213948 | 0.76 | SMN1; SMN2 (0.38) | ALDH1A1MAPK1 | |
| SCHEMBL213252 | 0.76 | HIF1A (0.40) | — | |
| SCHEMBL4345016 | 0.75 | TP53 (0.39) | L3MBTL1HSD17B10MAPTKDM4EPOLB | |
| SCHEMBL4347050 | 0.75 | MAPT (0.38) | L3MBTL1HSD17B10MAPTKDM4EALDH1A1 | |
| SCHEMBL213609 | 0.74 | P2RX7 (0.35) | L3MBTL1HSD17B10KDM4EALDH1A1MAPK1 | |
| SCHEMBL210169 | 0.74 | RAD52 (0.41) | L3MBTL1MAPTKDM4EPOLBALDH1A1 | |
| SCHEMBL210702 | 0.73 | NR3C1 (0.38) | MAPTKDM4EPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | S1PR1 3321/4885L3MBTL1 4642/4885HSD17B10 2636/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | S1PR1 3321/4885L3MBTL1 4642/4885HSD17B10 2636/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | S1PR1 3321/4885L3MBTL1 4642/4885HSD17B10 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.